Literature DB >> 27604840

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.

D C Chen1, X D Du2, G Z Yin2, K B Yang1, Y Nie1, N Wang1, Y L Li1, M H Xiu1, S C He3, F D Yang1, R Y Cho4, T R Kosten5, J C Soares4, J P Zhao6, X Y Zhang1.   

Abstract

BACKGROUND: Schizophrenia patients have a higher prevalence of type 2 diabetes mellitus with impaired glucose tolerance (IGT) than normals. We examined the relationship between IGT and clinical phenotypes or cognitive deficits in first-episode, drug-naïve (FEDN) Han Chinese patients with schizophrenia.
METHOD: A total of 175 in-patients were compared with 31 healthy controls on anthropometric measures and fasting plasma levels of glucose, insulin and lipids. They were also compared using a 75 g oral glucose tolerance test and the homeostasis model assessment of insulin resistance (HOMA-IR). Neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery (MCCB). Patient psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS).
RESULTS: Of the patients, 24.5% had IGT compared with none of the controls, and they also had significantly higher levels of fasting blood glucose and 2-h glucose after an oral glucose load, and were more insulin resistant. Compared with those patients with normal glucose tolerance, the IGT patients were older, had a later age of onset, higher waist or hip circumference and body mass index, higher levels of low-density lipoprotein and triglycerides and higher insulin resistance. Furthermore, IGT patients had higher PANSS total and negative symptom subscale scores, but no greater cognitive impairment except on the emotional intelligence index of the MCCB.
CONCLUSIONS: IGT occurs with greater frequency in FEDN schizophrenia, and shows association with demographic and anthropometric parameters, as well as with clinical symptoms but minimally with cognitive impairment during the early course of the disorder.

Entities:  

Keywords:  Cognition; drug-naïve patients; first-episode schizophrenia; glycometabolism; psychopathology

Mesh:

Substances:

Year:  2016        PMID: 27604840     DOI: 10.1017/S0033291716001902

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  18 in total

1.  Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia.

Authors:  Xiangyang Zhang; Mi Yang; Xiangdong Du; Wei Liao; Dachun Chen; Fengmei Fan; Meihong Xiu; Qiufang Jia; Yuping Ning; Xingbing Huang; Fengchun Wu; Jair C Soares; Bo Cao; Li Wang; Huafu Chen
Journal:  Mol Psychiatry       Date:  2019-08-13       Impact factor: 15.992

Review 2.  Astrocyte Bioenergetics and Major Psychiatric Disorders.

Authors:  Ivan V Maly; Michael J Morales; Mikhail V Pletnikov
Journal:  Adv Neurobiol       Date:  2021

3.  Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.

Authors:  Marianne Foiselle; Susana Barbosa; Ophélia Godin; Ching-Lien Wu; Wahid Boukouaci; Myrtille Andre; Bruno Aouizerate; Fabrice Berna; Caroline Barau; Delphine Capdevielle; Pierre Vidailhet; Isabelle Chereau; Laetitia Davidovic; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Guillaume Fond; Sylvain Leigner; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Emanuela Martinuzzi; Christine Passerieux; Romain Rey; Baptiste Pignon; Mathieu Urbach; Franck Schürhoff; Nicolas Glaichenhaus; Marion Leboyer; Ryad Tamouza
Journal:  Brain Behav Immun Health       Date:  2022-03-29

4.  Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis.

Authors:  Suat Kucukgoncu; Urska Kosir; Elton Zhou; Erin Sullivan; Vinod H Srihari; Cenk Tek
Journal:  Early Interv Psychiatry       Date:  2018-10-02       Impact factor: 2.732

5.  The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.

Authors:  Ghada S Mahmoud; Ghada Hosny; Sally A Sayed
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-04-15

6.  Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls.

Authors:  Yang Tian; Dongmei Wang; Gaoxia Wei; Jiesi Wang; Huixia Zhou; Hang Xu; Qilong Dai; Meihong Xiu; Dachun Chen; Li Wang; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2020-11-25       Impact factor: 4.530

Review 7.  Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Toby Pillinger; Katherine Beck; Cristian Gobjila; Jacek G Donocik; Sameer Jauhar; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2017-03-01       Impact factor: 21.596

8.  Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.

Authors:  Zachary Freyberg; Despoina Aslanoglou; Ripal Shah; Jacob S Ballon
Journal:  Front Neurosci       Date:  2017-07-28       Impact factor: 4.677

9.  Correlations between age, biomedical variables, and cognition in patients with schizophrenia.

Authors:  Wei Tang; Kai-Li Fan; Shu-Zhen Zhao; Yao-Yao Zhang; Yan Li; Sheng-Min Shao; Zheng Wang; Jiang-Qiong Ke
Journal:  Schizophr Res Cogn       Date:  2020-06-16

Review 10.  Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.

Authors:  Toby Pillinger; Katherine Beck; Brendon Stubbs; Oliver D Howes
Journal:  Br J Psychiatry       Date:  2017-10-05       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.